## **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

	SECOR	WASHINGTON, D.C. 20549	
		FORM 8-K	
		Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934	
		Date of Report (date of earliest event reported October 1, 2021	):
	D	efinitive Healthcare Co	rp.
		(Exact name of registrant as specified in its charter)	
		Commission file number 1-40815	
	Delaware (State of incorporation)		86-3988281 (I.R.S. Employer Identification No.)
		550 Cochituate Rd Framingham, MA 01701 (Address of principal executive offices)	
		(508) 720-4224 Registrant's telephone number, including area code	
		Not Applicable (Former Name or Former Address, if Changed Since Last Report)	
(	Check the appropriate box below if the Fo	rm 8-K filing is intended to simultaneously satisfy the filing following provisions:	g obligation of the registrant under any of the
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pu	ursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 2	240.13e-4(c))
Sec	urities registered pursuant to Section 12(b)	) of the Act:	
	Title of Each Class	Trading Symbol	Name of Each Exchange

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

DH

Emerging growth company ⊠

**Title of Each Class** Class A Common Stock, \$0.001 par value

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

# Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On October 1, 2021, Ms. Kathleen A. Winters was elected to the board of directors (the "Board") and the Audit Committee of the Board of Definitive Healthcare Corp. Ms. Winters served as the Chief Financial Officer of ADP, Inc. from 2019 through September 30, 2021. Prior to joining ADP, Inc., she served as Chief Financial Officer of MSCI Inc. Ms. Winters previously spent 14 years in various leadership roles at Honeywell International.

## **Item 9.01 Financial Statements and Exhibits**

## (d) Exhibits

- 99.1 Press Release, dated October 1, 2021.
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DEFINITIVE HEALTHCARE CORP.

By: /s/ David Samuels
Name: David Samuels
Title: Chief Legal Officer

Date: October 1, 2021

## Definitive Healthcare Appoints Kathleen A. Winters to Board of Directors

**FRAMINGHAM, MA (October 1, 2021) – <u>Definitive Healthcare</u> (NASDAQ: DH), an industry leader in healthcare commercial intelligence, today announced the appointment of Kathleen A. Winters to its Board of Directors and its Audit Committee.** 

"Kathleen's wealth of financial and operational leadership experience from numerous publicly-traded companies will be a tremendous asset to Definitive Healthcare and we're incredibly excited to welcome her to the Board," said Jason Krantz, CEO and founder of Definitive Healthcare. "Her insights and counsel will be critical as we enter the next phase of our journey as a public company and continue our work to enhance the healthcare commercial intelligence we provide our customers."

Winters recently retired from her role as Chief Financial Officer at ADP (NASDAQ:ADP), where she was responsible for leading the global finance organization, representing the company to investors, lenders and rating agencies and played a significant role in driving the company's strategy, growth and operational effectiveness. Prior to ADP, she served as Chief Financial Officer at MSCI, Inc. (NYSE: MSCI), a leading provider of investment decision support tools including indexes, for institutional investors for three years. Before that, she spent 14 years in various financial leadership roles at Honeywell International (NASDAQ: HON).

"Definitive Healthcare is doing great work to help organizations make sense of the complex healthcare ecosystem," said Winters. "I'm excited to join the Board at this pivotal moment in the company's trajectory and I look forward to working with the leadership team as they continue to bring valuable healthcare insights to customers."

#### **About Definitive Healthcare**

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow's healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at <u>definitivehc.com</u>.

### **Media Contact:**

Danielle Johns PR Manager, Definitive Healthcare djohns@definitivehc.com

## **Investor Relations Contact:**

Brian Denyeau brian.denyeau@icrinc.com